ADIM
CSTL icon

Alpha DNA Investment Management’s Castle Biosciences CSTL Stock Holding History

Alpha DNA Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,174
Closed -$404K – 53
2024
Q4 		$404K Sell
15,174
-1,589
-9% -$48.4K 0.15% 171
2024
Q3 		$478K Sell
16,763
-3,275
-16% -$83.4K 0.18% 123
2024
Q2 		$436K Sell
20,038
-3,002
-13% -$66.9K 0.17% 138
2024
Q1 		$510K Buy
+23,040
New +$501K 0.19% 145
2023
Q4 		– Sell
-29,399
Closed -$497K – 199
2023
Q3 		$497K Buy
+29,399
New +$514K 0.2% 140

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alpha DNA Investment Management's CSTL Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 15,174 shares — an estimated $404K sold.

Alpha DNA Investment Management first reported a position in CSTL in Q3 2023 and held it in 5 quarters. The position peaked at $510K in Q1 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Alpha DNA Investment Management reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Alpha DNA Investment Management sold 15,174 Castle Biosciences shares in Q1 2025, an estimated $404K.
  • Alpha DNA Investment Management first reported a position in Castle Biosciences in Q3 2023 and held it in 5 quarters.
  • Alpha DNA Investment Management's Castle Biosciences position peaked at $510K in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.